Tarsus Pharmaceuticals President, CEO and Board Chair Bobak R. Azamian sold 10,000 shares at $80.06 per share on Sep. 2, 2026. After the transaction, Azamian owned 837,991 shares, giving investors the reported size, price and remaining shareholding tied to the insider transaction.
Key Highlights
- The transaction occurred on Sep. 2, 2026.
- Bobak R. Azamian owned 837,991 shares after the sale.
- Azamian serves as Tarsus Pharmaceuticals’ President, CEO and Board Chair.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) saw President, CEO and Board Chair Bobak R. Azamian sell 10,000 shares at $80.06 per share. The transaction was completed on Sep. 2, 2026.
$80.06 Per-Share Insider Sale
Azamian’s transaction was recorded under code S. The sale took place while he served as Tarsus Pharmaceuticals’ President, CEO and Board Chair. Following the transaction, Azamian owned 837,991 shares of Tarsus Pharmaceuticals. The reported ownership figure represents Azamian’s ownership after the transaction. Tarsus Pharmaceuticals’ disclosure connects the sale to the specific per-share price of $80.06 and identifies Sep. 2, 2026, as the transaction date.
FAQs
Q: How many Tarsus Pharmaceuticals shares did Bobak Azamian sell?
A: Bobak R. Azamian sold 10,000 Tarsus Pharmaceuticals shares at $80.06 per share. The transaction occurred on Sep. 2, 2026, and the filing identifies him as the company’s President, CEO and Board Chair.
Q: What does the Tarsus Pharmaceuticals insider sale mean for investors?
A: The transaction leaves Azamian with 837,991 shares in Tarsus Pharmaceuticals. That figure is the reported post-transaction ownership tied to the insider sale.
Q: Who is Bobak Azamian at Tarsus Pharmaceuticals?
A: Bobak R. Azamian is Tarsus Pharmaceuticals’ President, CEO and Board Chair. He sold 10,000 shares at $80.06 per share on Sep. 2, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.